Investigational Drug Details
| Drug ID: | D185 |
| Drug Name: | Inulin |
| Synonyms: | Inulin |
| Type: | Chemical drug |
| DrugBank ID: | DB00638 |
| DrugBank Description: | A starch found in the tubers and roots of many plants. Since it is hydrolyzable to fructose, it is classified as a fructosan. It has been used in physiologic investigation for determination of the rate of glomerular function. |
| PubChem ID: | 24763 |
| CasNo: | 9005-80-5 |
| Repositioning for NAFLD: | Yes |
| SMILES: | O([C@@]1(O[C@@H]([C@@H](O)[C@@H]1O)CO)CO[C@@]1(O[C@@H]([C@@H](O)[C@@H]1O)CO)CO[C@@]1(O[C@@H]([C@@H](O)[C@@H]1O)CO)CO[C@@]1(O[C@@H]([C@@H](O)[C@@H]1O)CO)CO[C@@]1(O[C@@H]([C@@H](O)[C@@H]1O)CO)CO[C@@]1(O[C@@H]([C@@H](O)[C@@H]1O)CO)CO[C@@]1(O[C@@H]([C@@H](O)[C@@H]1O)CO)CO[C@@]1(O[C@@H]([C@@H](O)[C@@H]1O)CO)CO[C@@]1(O[C@@H]([C@@H](O)[C@@H]1O)CO)CO[C@@]1(O[C@@H]([C@@H](O)[C@@H]1O)CO)CO[C@@]1(O[C@@H]([C@@H](O)[C@@H]1O)CO)CO[C@@]1(O[C@@H]([C@@H](O)[C@@H]1O)CO)CO[C@@]1(O[C@@H]([C@@H](O)[C@@H]1O)CO)CO[C@@]1(O[C@@H]([C@@H](O)[C@@H]1O)CO)CO[C@@]1(O[C@@H]([C@@H](O)[C@@H]1O)CO)CO[C@@]1(O[C@@H]([C@@H](O)[C@@H]1O)CO)CO[C@@]1(O[C@@H]([C@@H](O)[C@@H]1O)CO)CO[C@@]1(O[C@@H]([C@@H](O)[C@@H]1O)CO)CO[C@@]1(O[C@@H]([C@@H](O)[C@@H]1O)CO)CO)C[C@@]1(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(OC[C@@]%12(OC[C@@]%13(OC[C@]%14(O[C@@H]([C@@H](O)[C@@H]%14O)CO)OC[C@]%14(O[C@@H]([C@@H](O)[C@@H]%14O)CO)OC[C@]%14(O[C@@H]([C@@H](O)[C@@H]%14O)CO)OC[C@]%14(O[C@@H]([C@@H](O)[C@@H]%14O)CO)OC[C@]%14(O[C@@H]([C@@H](O)[C@@H]%14O)CO)O[C@H]%14O[C@@H]([C@@H](O)[C@H](O)[C@H]%14O)CO)O[C@@H]([C@@H](O)[C@@H]%13O)CO)O[C@@H]([C@@H](O)[C@@H]%12O)CO)O[C@@H]([C@@H](O)[C@@H]%11O)CO)O[C@@H]([C@@H](O)[C@@H]%10O)CO)O[C@@H]([C@@H](O)[C@@H]9O)CO)O[C@@H]([C@@H](O)[C@@H]8O)CO)O[C@@H]([C@@H](O)[C@@H]7O)CO)O[C@@H]([C@@H](O)[C@@H]6O)CO)O[C@@H]([C@@H](O)[C@@H]5O)CO)O[C@@H]([C@@H](O)[C@@H]4O)CO)O[C@@H]([C@@H](O)[C@@H]3O)CO)O[C@@H]([C@@H](O)[C@@H]2O)CO)O[C@@H]([C@@H](O)[C@@H]1O)CO |
| Structure: |
|
| InChiKey: | JYJIGFIDKWBXDU-MNNPPOADSA-N |
| Molecular Weight: | 6179.373 |
| DrugBank Targets: | Cycloinulo-oligosaccharide fructanotransferase binder |
| DrugBank MoA: | As a diagnostic agent, inulin is readily soluble and essentially indigestible. It readily passes through the blood and into the urine. It is neither secreted nor resorbed by the kidney making it an excellent indicator for renal clearance rates. The inulin clearance test has largely been succeeded by the creatinine clearance test as a measure of glomerular filtration rate. Inulin is a hypoglycemic agent. Since it is not digestible by human enzymes ptyalin and amylase, inulin passes through much of the digestive system intact. It is only in the colon that bacteria metabolise inulin, with the release of significant quantities of carbon dioxide and/or methane. Because inulin is not broken down into simple sugars (monosaccharides) by normal digestion, it does not elevate blood sugar levels, hence, helping diabetics regulate blood sugar levels. |
| DrugBank Pharmacology: | The inulin test is a procedure by which the filtering capacity of the glomeruli (the main filtering structures of the kidney) is determined by measuring the rate at which inulin, the test substance, is cleared from blood plasma. Inulin is one of the more suitable and accurate substance to measure because it is a small, inert polysaccharide molecule that readily passes through the glomeruli. The inulin clearance test is performed by injecting inulin, waiting for it to be distributed, and then measuring plasma and urine inulin concentrations by various assays. As nutraceutical agents inulins may have antitumor, antimicrobial, hypolipidemic and hypoglycemic actions. They may also help to improve mineral absorption and balance and may have antiosteoporotic activity. |
| DrugBank Indication: | Historically used in an important medical test of renal function, specifically a measure of glomerular filtration rate. Sometimes used to help relieve symptoms of diabetes mellitus - a condition characterised by hyperglycemia and/or hyperinsulinemia. |
| Targets: | CFT binder |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Clinical trial on-going (NCT03914495) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0503 | IRCT20100524004010N23 | Not applicable | Not Recruiting | No Results Available | 18/04/2018 | 21 May 2018 | Details |
| L0753 | NCT03914495 | Not applicable | Recruiting | No Results Available | 11/04/2019 | 31 January 2022 | Details |
| L0858 | NCT02642172 | Not applicable | Not recruiting | No Results Available | 13/12/2015 | 13 September 2021 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00055 | 35240510 | Biochem Biophys Res Commun | Inulin activates FXR-FGF15 signaling and further increases bile acids excretion in non-alcoholic fatty liver disease mice. | Details |
| A00515 | 35055177 | Int J Mol Sci | Inulin Improves Diet-Induced Hepatic Steatosis and Increases Intestinal Akkermansia Genus Level. | Details |
| A01352 | 34778099 | Front Cell Infect Microbiol | Gut Microbiota, Glucose, Lipid, and Water-Electrolyte Metabolism in Children With Nonalcoholic Fatty Liver Disease. | Details |
| A02013 | 34530928 | Microbiome | Commensal microbe-derived acetate suppresses NAFLD/NASH development via hepatic FFAR2 signalling in mice. | Details |
| A02257 | 34445384 | Int J Mol Sci | The Obscure Effect of Tribulus terrestris Saponins Plus Inulin on Liver Morphology, Liver Fatty Acids, Plasma Glucose, and Lipid Profile in SD Rats with and without Induced Type 2 Diabetes Mellitus. | Details |
| A02491 | 34355155 | JHEP Rep | A dynamic association between myosteatosis and liver stiffness: Results from a prospective interventional study in obese patients. | Details |
| A02973 | 34177920 | Front Immunol | Prebiotic Inulin and Sodium Butyrate Attenuate Obesity-Induced Intestinal Barrier Dysfunction by Induction of Antimicrobial Peptides. | Details |
| A03206 | 34090052 | Biomed Pharmacother | Probiotic-prebiotic-synbiotic modulation of (YAP1, LATS1 and NF2 mRNAs/miR-1205/lncRNA SRD5A3-AS1) panel in NASH animal model. | Details |
| A03391 | 34019353 | Vopr Pitan | [Specialized products for dietary correction of the diet of patients with non-alcoholic steatohepatitis]. | Details |
| A04394 | 33636349 | Pharmacol Res | Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease. | Details |
| A05062 | 33390939 | Front Pharmacol | Inulin Exerts Beneficial Effects on Non-Alcoholic Fatty Liver Disease via Modulating gut Microbiome and Suppressing the Lipopolysaccharide-Toll-Like Receptor 4-Mψ-Nuclear Factor-κB-Nod-Like Receptor Protein 3 Pathway via gut-Liver Axis in Mice. | Details |
| A05346 | 33292701 | Biomark Res | Dysregulated bile acid receptor-mediated signaling and IL-17A induction are implicated in diet-associated hepatic health and cognitive function. | Details |
| A05614 | 33187278 | Nutrients | The Relationship between Prebiotic Supplementation and Anthropometric and Biochemical Parameters in Patients with NAFLD-A Systematic Review and Meta-Analysis of Randomized Controlled Trials. | Details |
| A05628 | 33183606 | Carbohydr Polym | Friend or foe? The roles of inulin-type fructans. | Details |
| A06488 | 32859329 | Clin Nutr ESPEN | The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: A randomized, placebo-controlled, clinical trial. | Details |
| A07694 | 32389170 | Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi | [Inulin increases the proportion of monocytic myeloid-derived suppressor cells in peripheral blood, liver, spleen and regulates the secretion of plasma inflammatory cytokines in mice with non-alcoholic fatty liver disease]. | Details |
| A08143 | 32230987 | Nutrients | Randomised Double-Blind Placebo-Controlled Trial of Inulin with Metronidazole in Non-Alcoholic Fatty Liver Disease (NAFLD). | Details |
| A10092 | 31491513 | Int J Biol Macromol | MDG-1, an Ophiopogon polysaccharide, restrains process of non-alcoholic fatty liver disease via modulating the gut-liver axis. | Details |
| A11284 | 30958562 | Histol Histopathol | Modulatory effect of inulin with soya isoflavones on plasma lipid profile and liver SCD-18 index in rats with induced type-2 diabetes mellitus. | Details |
| A12040 | 30628563 | Proc Nutr Soc | Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis. | Details |